Quantum BioPharma Advances Lucid-MS and unbuzzd in Podcast

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well as the commercial opportunity surrounding its unbuzzd product. Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial, which could represent the candidate’s first administration to human MS patients. He also discussed unbuzzd, a commercially available product designed to accelerate alcohol metabolism, underscoring Quantum BioPharma’s strategy of combining clinical-stage pharmaceutical development with commercial opportunities across neurodegenerative, metabolic and alcohol-misuse conditions.

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Additionally, Quantum BioPharma invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.84% of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products for pharmaceutical and medical uses. For more details, visit the company’s newsroom at https://ibn.fm/QNTM.

The BioMedWire Podcast episode provides a deep dive into Quantum BioPharma’s dual strategy of advancing a promising MS drug candidate while generating revenue from a commercial product. This approach highlights the company’s ability to balance high-risk drug development with near-term sales from unbuzzd, which is available online at www.unbuzzd.com. The podcast also underscores the potential of Lucid-MS to address mobility damage in MS patients, a significant unmet need. As Quantum BioPharma progresses toward its Phase 2 trial, investors and patients alike will be watching closely.